"DX1 and DX3 have all the hallmarks of a potential buyout - all these animal studies showing multiple novel characteristics of the DX family + the news of an imminent phase I trial will in my opinion definitely position Patrys well for a pre-clinical buyout."
My thoughts are if the company announces their launch of phase 1 trials then there won't be a buyout until the results of that trial come through. Best case for investors is a big pharma will put an offer on the table that is dependent on the results, with an initial immediate payment that may supplement phase 1 costs.
Otherwise if Patrys already has enough money to get through phase 1 trials, they're better off getting the safety data before allowing a buyout in say a years time. If they're months from starting phase 1, looking at the SP now you have to ask how much the top holders have to gain from a buyout now vs in a years time after they have the human dataset to prove safety and efficacy, creating a much higher-value product.
If a big pharma came to the table now, in preclinical, they could offer 5c/share or $100m for the company, a 100% premium on today's price. Seems like a good offer on paper, especially for a product that has no clinical validation in humans. Investors double their money as of today. Would they be willing to offer 10c/share ($200m), a 300% increase? Other side of the coin is what the minimum value the major shareholders are looking to get out of their investment, because they'll control the vote. Why would they accept a $200m buyout when they could wait 12 months and with supporting clinical evidence expect say 25c/share ($500m), a 900% increase.
These are all obviously hypothetical numbers I've picked out of the air and is in no way investment advice. I believe the thought process to be relatively logical though. And I agree with you that Patrys is well positioned for a buyout, My opinion is that I'd be surprised if it happens before the phase 1 trial when they're also well positioned to run the trial first. Our opinions don't have to match, I appreciate the discussion either way.
- Forums
- ASX - By Stock
- Ann: New Mechanism By Which PAT-DX1 May Reduce Cancer Metastasis
"DX1 and DX3 have all the hallmarks of a potential buyout - all...
-
-
- There are more pages in this discussion • 68 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAB (ASX) to my watchlist
|
|||||
Last
0.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.34M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 1853666 | 0.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.7¢ | 3325244 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 1853666 | 0.006 |
16 | 8715158 | 0.005 |
11 | 6064000 | 0.004 |
13 | 6400516 | 0.003 |
5 | 2522000 | 0.002 |
Price($) | Vol. | No. |
---|---|---|
0.007 | 3325244 | 5 |
0.008 | 2781393 | 7 |
0.009 | 1080000 | 2 |
0.010 | 396000 | 5 |
0.011 | 1000000 | 1 |
Last trade - 16.12pm 16/08/2024 (20 minute delay) ? |
Featured News
PAB (ASX) Chart |
Day chart unavailable